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Abstract
The extent of tight junction (TJ) formation is one of many factors that regulate motility, invasion, and metastasis.
Claudins are required for the formation and maintenance of TJs. Claudin-3 (CLDN3) and claudin-4 (CLDN4) are highly
expressed in themajority of ovarian cancers. We report here that CLDN3 and CLDN4 each serve to constrain the growth
of human 2008 cancer xenografts and limit metastatic potential. Knockdownof CLDN3 increased in vivo growth rate by
2.3-fold and knockdown of CLDN4 by 3.7-fold in the absence of significant change in in vitro growth rate. Both types of
tumors exhibited increase in birth rate asmeasured by Ki67 staining and decrease in death rate as reflected by terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Knockdown of either claudin did not alter ex-
pression of other TJ protein but did reduce TJ formation asmeasured by transepithelial resistance and paracellular flux
of dextran, enhance migration and invasion in in vitro assays, and increase lung colonization following intravenous
injection. Knockdown of CLDN3 and CLDN4 increased total lung metastatic burden by 1.7-fold and 2.4-fold, respec-
tively. Loss of either CLDN3 or CLDN4 resulted in down-regulation of E-cadherin mRNA and protein, increased inhib-
itory phosphorylation of glycogen synthase kinase-3β (GSK-3β), and activation of β-catenin pathway signaling as
evidenced by increases in nuclear β-catenin, the dephosphorylated form of the protein, and transcriptional activity
of β-catenin/T-cell factor (TCF). We conclude that both CLDN3 and CLDN4 mediate interactions with other cells in vivo
that restrain growth and metastatic potential by sustaining expression of E-cadherin and limiting β-catenin signaling.
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Introduction
The mechanisms that control intercellular adhesion are central to
the process of invasion and metastasis. Normal epithelial cells are
held together by tight junctions (TJs), adherens junctions (AJs),
and gap junctions. These serve two roles: they mechanically link
cells, and they generate signals that are sent to the interior of the
cell to report on the extent of contact with neighbors and the extra-
cellular matrix [1,2]. One of the hallmarks of malignant transforma-
tion of epithelia is that these connections, particularly TJ, are lost
[3–5]. Disassembly or remodeling of TJs can cause loss of cell polar-
ity and an increase in motility and invasiveness [6–8], and there is
an association between the loss of cell-cell adhesion structures and
metastasis in many epithelial cancers [9].
Normal ovarian surface cuboidal epithelial cells do not express
either claudin-3 (CLDN3) or claudin-4 (CLDN4); however, CLDN3
and CLDN4 are expressed at high levels in as many as 92% of ovarian
cancers [10,11]. Initial studies based on the idea that the ovarian can-
cers arose from the ovarian surface cuboidal epithelium concluded that
CLDN3 and CLDN4 were upregulated in ovarian cancers [12–16].
However, recent studies favor the concept that these tumors arise from
the distal Fallopian tube, which expresses both of these claudins [17–
20]. Recent expression profiling studies have demonstrated a wide
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range of CLDN3 and CLDN4 expression among epithelial ovarian
cancers with a substantial fraction having low-level expression [21].
Such low expression has been linked to a mesenchymal pattern and
poor prognosis in breast [22], esophageal [23], colon [24,25], and
pancreatic carcinoma [26]. What role these proteins serve in ovarian
cancers is largely unknown and data from studies addressing this ques-
tion have yielded conflicting results (reviewed in [27–29]). For exam-
ple, in one study, low CLDN3 protein expression was found to be
associated with a trend toward poor survival in 115 primary ovarian
carcinomas [16]. However, in another study, high CLDN3 was cor-
related with shorter survival [10]. It is generally believed that claudin
expression is deregulated in cancer in a complex and organ-dependent
manner, and what role these proteins serve in ovarian cancers remains
poorly defined.
The concept that the claudins of the TJ can regulate tumor cell be-
havior has precedence in the well-documented ability of E-cadherin,
the major structural protein of the AJ, to do this. Loss of E-cadherin
is a hallmark of the epithelial-to-mesenchymal transition (EMT)
through which many investigators believe tumor cells must pass to
become metastatic [8,30,31]. Passage through the EMT is widely
reported to result in increased growth rate, enhanced metastatic poten-
tial, drug resistance, and the acquisition of stem cell characteristics
[32]. The EMT generates cells with properties of stem cells [33–35].
In ovarian cancer cell lines, knockdown of E-cadherin has been
reported to increase tumor cell growth and constitutive activation of
phosphoinositide 3-kinase (PI3K)/Akt signaling. Silencing of E-cadherin
releases membrane-bound β-catenin and enhances nuclear β-catenin sig-
naling, an effect augmented by inactivation of GSK-3β by the PI3K/Akt
pathway [36]. Loss of E-cadherin staining is common as ovarian cancer
progresses and this is associated with more extensive peritoneal dissem-
ination [37] as a result of up-regulation of the α5 integrin that results in
enhanced invasiveness and adhesion to the peritoneal surface [38]. Thus,
although the role of CLDN3 and CLDN4 found in TJ is not well
defined, the role of a major structural protein of the AJ in controlling
tumor cell behavior is well established and provides a precedent for
analysis of the influence of claudins.
There are now several lines of indirect evidence indicating that loss
of CLDN3 and CLDN4 expression is associated with poor prognosis.
Delocalization of claudins from membranes is common among trans-
formed cells, and in ovarian cancer, this is associated with increased
migration and invasion [39,40]. Disruption of cell-cell adhesions cor-
relates with progression, invasion, and metastasis in breast cancer
[9,41,42], and low expression of CLDN4 is associated with poor prog-
nosis in some subtypes of breast [22,43,44], pancreatic [26], and colon
cancers [24,25]. We report here that both CLDN3 and CLDN4
individually control the growth rate and metastasis potential of cancer
cells, processes that are fundamental to the biology and clinical manage-
ment of this disease. Constitutive knockdown of the expression of
either CLDN3 or CLDN4 in the putative ovarian cancer 2008 cells
increases in vivo growth rate and enhances metastasis in a nu/nu mouse
model. The magnitude of these effects is quite large and is accom-
panied by alterations in adhesion, migration, invasion, E-cadherin, and
activity of the canonical Wnt signaling pathway through β-catenin.
Materials and Methods
Cells, Cell Culture, and Transfection
The human cell lines 2008 and HEY were grown in RPMI 1640
supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml
streptomycin. Both of these cell lines were reported to be isolated from
patients with ovarian cancer [45,46]. However, DNA fingerprinting
has disclosed that the 2008 line may be related to the cervical carcinoma
cell line ME-180 (ATCC HTB-33) and that the HEY cell line may be
related to the neuronal cell line CRL-10442 (ATCC HCN-1A). Their
CLDN3 or CLDN4 knockdown or overexpressing sublines were cul-
tured in the presence of 10 μg/ml puromycin. Cultures were main-
tained at 37°C in a humidified atmosphere of 5% CO2 and 95% air.
For measurement of β-catenin transcriptional activity, the cells were
co-transfected with the firefly luciferase TOPflash TCF reporter and
control plasmid pCMXβgal by using the FuGENE transfection re-
agent (Roche Diagnostics, Mannheim, Germany) according to the
manufacturer’s instructions. Twenty-four hours after transfection, cells
were lysed in potassium phosphate buffer containing 1%Triton X-100,
and light emission was detected in the presence of luciferin by using a
microtiter plate luminometer (MicroBeta TriLux, Gaithersburg, MD).
The luciferase values were normalized for variations in transfection effi-
ciency by using the β-galactosidase internal control and are expressed
either as relative luciferase units or as fold stimulation of luciferase
activity compared with the designated control cultures. All of the trans-
fection results represent means of a minimum of three independent
transfections assayed in duplicate (±SEM).
Lentivirus-based Short Hairpin RNA Transduction
MISSION short hairpin RNA (shRNA) lentiviral transduction
particles for the CLDN3 and CLDN4 knockdown experiments were
obtained from Sigma (St Louis, MO). One of five CLDN3- or CLDN4-
specific shRNA constructs (shRNA sequence targeting CLDN3:
CCGGCGACCGCAAGGACTACGTCTACTC GAGTAGACG-
TAGTCCTTGCGGTCGTTTTTG; shRNA sequence targeting
CLDN4: CCGGG CAACATTGTCACCTCGCAGACTC-
GAGTCTGCGAGGTGACAATGTTGCTTTTTG) and one “non-
target” construct were transduced separately into 2008 cells. The
“nontarget” construct contained an shRNA sequence that did not target
any known human gene and served as a scrambled negative control.
Briefly, 2008 cells were transduced with the CLDN3- or CLDN4-
specific shRNA lentiviral particles at a ratio of five particles to one cell
for 24 hours in the presence of hexadimethrine bromide to improve
transduction efficiency. Afterward, the medium containing viral parti-
cles was removed and replaced with fresh medium containing 10 μg/ml
puromycin. Before lentiviral transduction, a puromycin titration was
performed that identified 10 μg/ml as the minimum puromycin con-
centration that caused complete death of 2008 cells after a 5-day incuba-
tion. CLDN3 or CLDN4 knockdown was confirmed using quantitative
reverse transcription–polymerase chain reaction (RT-PCR) andWestern
blot analysis by comparison to the parental 2008 cells and nontarget
shRNA cells (designated here as 2008-scb).
Immunoblot Analysis, Immunofluorescence,
Immunohistochemistry, and Confocal Microscopy
Immunoblot analysis was performed using the antibodies against
CLDN3, CLDN4, occludin, JAM-1, ZO-1, E-cadherin, and β-catenin.
For immunofluorescence analysis, cells were grown on polylysine-coated
eight-well chamber slides, fixed in 3.7% formaldehyde, and perme-
abilized in phosphate-buffered saline containing 0.2% Triton X-100,
and indirect immunofluorescence was performed as described pre-
viously [47]. The following antibodies were used: rabbit polyclonal
anti–claudin-3 (Invitrogen, Carlsbad, CA), mouse monoclonal anti–
claudin-4 (Abcam, Cambridge, MA), rabbit polyclonal anti-occludin
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(Abcam), mouse polyclonal anti–JAM-1 (Abcam), rabbit polyclonal
anti–ZO-1 (Zymed, Grand Island, NY), rabbit polyclonal anti–E-
cadherin (Santa Cruz Biotechnology, Santa Cruz, CA), and mouse
monoclonal anti–β-catenin and anti–dephospho–β-catenin (Cell Signal-
ing Technology, Danvers, MA). Immunohistochemistry was performed
on xenografted tumors either imbedded in paraffin or frozen in Tissue-
Tek OCT compound (Sakura Finetek USA, Torrance, CA) as described
previously [48]. Sections were stained with anti-Ki67, anti-CD31, and
anti–bromodeoxyuridine (BrdU) antibodies. Confocal microscopy was
performed with a Zeiss LSM510 confocal microscope system (Carl Zeiss,
Inc, Thornwood,NY). Cells were randomly selected for imaging taken in
0.5-μm sections. The number of Z-scan sections required to image a cell
ranged between 15 and 25. Data are shown as superimposed (stacked)
Z-scan images and as single confocal images.
Real-time PCR
RNA was extracted with TRIzol reagent (Invitrogen). First-strand
cDNA was synthesized using SuperScript II reverse transcriptase
(Invitrogen) and random primers. Real-time PCR was performed
using the Bio-Rad iCycler iQ detection system in the presence of
SYBR Green I dye (Bio-Rad Laboratories, Inc, Hercules, CA). β-Actin
was used as reference gene and relative mRNA levels were determined
using the 2(−ΔΔCt) method. A 1-unit difference of C t value represents a
two-fold difference in the level of mRNA.
Measurement of Transepithelial Electrical Resistance and
Paracellular Permeability
One hundred thousand cells in 0.5 ml of complete medium were
seeded into 12-mm transwell insert with a membrane pore size of
0.45 μm (Millipore, Carrigtwohill, Ireland) placed in 24-well plate
containing 0.75 ml of the growth medium. Transepithelial elec-
trical resistance (TER) was measured using an EVOM-Epithelial
Voltohmmeter (World Precision Instruments, NewHaven, CT). Read-
ings were taken 3 days after seeding the cells. The TER values were
calculated by subtracting the blank values from the sample values and
normalized to the growth area of the monolayer.
The paracellular permeability assay measured the diffusion of
fluorescein isothiocyanate (FITC)-labeled dextran (FITC-dextran,
4 kDa) across a cell layer grown on a membrane of transwell insert.
The cells were seeded (1 × 105 cells per insert) and cultured to form
a monolayer for 3 days. The culture medium was then replaced with
prewarmed Ringer’s solution a few minutes before the addition of
FITC-dextran (1 mg/ml in Ringer’s solution). Five hundred microliters
of FITC-dextran was added to the upper chamber and 100 μl of the sam-
ples were removed from the lower chamber after 1 hour. Fluorescence was
measured on a FLUOstar OPTIMA plate reader (Ex485 nm/Em544 nm).
The diffusion of FITC-dextran across the insert without cells was also
measured to serve as 100% permeability.
In Vivo Tumor Growth
Female nu/nu mice at age 5 to 6 weeks were purchased from
Charles River Laboratories (Wilmington, MA). All work performed
with animals was in accordance with and approved by the Institu-
tional Animal Care and Use Committee at the University of California,
San Diego. To determine the in vivo growth potential, the cells were
inoculated subcutaneously (SC) on two sites of a nude mouse. Tumor
volume was measured every 2 days and calculated using the formula:
length × width2/2 and plotted as a function of time to generate the
in vivo growth curves.
In Vitro Cell Migration and Invasion Assay
The invasive capabilities of the cells were determined using a
modified Boyden chamber invasion assay [49]. Cells were cultured
to about 80% confluence and serum starved overnight. Transwell
inserts (BD Biosciences, San Jose, CA) of 8-μm pore size were coated
with 150 μl of 1:60 diluted Matrigel (BD Biosciences). Three hundred
thousand cells after overnight starvation were plated onto the top of
each of the coated filters in 150 μl of serum-free medium. Three
hundred microliters of the same medium containing 20% fetal calf
serum was placed in the lower chamber to act as a chemoattractant.
After 24 hours of culture, cells that did not migrate or invade through
the pores of the transwell inserts will be manually removed with cotton
swabs and the inserts were fixed in cold methanol for 10 minutes and
then stained with 0.01% crystal violet in 20% ethanol. After washing
thoroughly, colorimetric readings were taken at 595 nm. The experi-
ment was performed twice with each sample in triplicate. To assess cell
migration, assays were carried out as above except that cells were plated
on top of uncoated (Matrigel-free) inserts.
Measurement of Migration Using Wound-healing/
Scratch Assay
Cells were grown to confluence on 60-mm cell culture dishes and
a scratch was made through the cell monolayer using a pipette tip.
After washing with Hank’s balanced salt solution, fresh culture medium
was added and the cells were incubated at 37°C in a humid environ-
ment with 5% CO2. Wound closure was observed and photographed
at 0, 12, and 24 hours after making the scratch to monitor the invasion
of cells into the wounded area. The experiment was performed twice
and assayed in triplicate.
In Vivo Metastasis Study
To determine whether changes in migration and invasiveness de-
tected in vitro translate into differences in metastatic potential in vivo,
6-week-old female nude mice were injected with 1 × 106 Ds-Red–
expressing cells of 2008, CLDN3KD, or CLDN4KD in the tail vein.
Mice were sacrificed and explored when they appeared premorbid.
Postmortem external fluorescent images were obtained by a highly sen-
sitive in vivo imaging system (IVIS 200; Caliper, Virginia Beach, VA).
Each mouse underwent laparotomy and median sternotomy. Red
fluorescent protein (RFP) expression was visualized in the whole-body
image system, facilitating identification of metastatic tumors. After
obtaining open images, lungs, liver, spleen, and kidneys were removed
and were thoroughly examined for any evidence of metastasis using
both fluorescence imaging and histopathologic analysis.
Statistical Analysis
All data are presented as the means ± SD. Statistical analysis was
evaluated by the unpaired Student’s t test, with reference to respective
control and expressed as P values presented in the Results section.
Results
Suppression of CLDN3 or CLDN4 Expression Promotes
Tumor Growth In Vivo
To investigate the role of CLND3 and CLDN4, we constitutively
knocked down their expression in the human carcinoma cell line 2008
using shRNAi vectors. In the CLDN3KD cells, the CLDN3 mRNA
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level was reduced to 5% of control and the protein level to 26%
of control. In the CLDN4KD cells, the CLDN4 mRNA level was
reduced to 12% of control and the protein level to 16% of control.
Transduction of 2008 cells with a vector expressing a scrambled
shRNAi that did not target any human gene did not alter the mRNA
or protein level of either CLDN3 or CLDN4 (Figure W1, A and B).
Interestingly, we found that knocking down the expression of CLDN3
also decreased the expression of CLDN4 and vice versa. Knockdown
of CLDN3 reduced CLDN4 mRNA to 14% of control and protein
to 38%. Knockdown of CLDN4 reduced CLDN3 mRNA to 36%
of control and protein to 49%. Rather than being due to an off-target
effect of the two shRNAs, this can be explained by the fact that
the promoters for both genes are sensitive to the same transcriptional
repressors that are potentially activated when either one or the other
mRNA is reduced [23,50,51].
Knockdown of these claudins did not produce any change in the
rate of proliferation of the cells in vitro (Figure W1C ) and produced
only minor perturbations of cell cycle phase distribution (FigureW1D).
In contrast, as shown in Figure 1A, although tumors developed at all
sites after SC inoculation, in vivo the CLDN3KD tumors grew 2.3-fold
faster (P = 0.007), and the CLDN4KD tumor 3.7-fold (P = 0.001)
faster, than the parental 2008 tumors. The effect of CLDN3 or
CLDN4 knockdown on in vivo tumor growth was specific as reintro-
duction of an siRNA-resistant CLDN3 or CLDN4 construct into the
knockdown cells significantly reduced the tumor growth (Figure 1B;
P = 0.022, CLDN3KD vs CLDN3KD-3 rsc; P = 0.001, CLDN4KD
vs CLDN4KD-4 rsc). As shown in Figure 1C , the birth rate in the
CLDN3KD and CLDN4KD tumors, as reflected by Ki67 staining,
was 2.9-fold and 6.7-fold higher in the CLDN3KD and CLDN4KD
tumors, respectively. This was accompanied by a 2.0-fold and 3.7-fold
Figure 1. CLDN3 and CLDN4 control the growth of ovarian tumor xenografts in vivo. (A) Relative growth rate of 2008 (▪), CLDN3KD (⋄),and CLDN4KD (◯) tumors after SC inoculation of 1 × 106 cells in nu/nu mice (n = 16 for each tumor type). (B) Re-expression of siRNA-
resistant CLDN3 or CLDN4 in the claudin knockdown cells, designated here as CLDN3KD-3 rescue and CLDN4KD-4 rescue, slowed the
tumor growth in vivo. Six synonymous point mutations were introduced in shRNA target regions in full-length CLDN3 or CLDN4 cDNA
and the siRNA-resistant cDNAs were cloned into pLVX-mCherry vector. Following infection with lentivirus produced from this vector in
HEK298T cells, 2008 cells expressing high levels of the protein were isolated by fluorescence-activated cell sorting (FACS) and used
to inoculate SC in nu/nu mice (n = 16 for each tumor type). (C) Quantification of Ki67-positive and TUNEL-positive cells and density of
CD31-positive vessels in 2008, CLDN3KD, and CLDN4KD tumors.
Neoplasia Vol. 14, No. 10, 2012 Tight Junction Proteins Claudin-3 and Claudin-4 Shang et al. 977
reduction in death rate as evidenced by TUNEL staining and a dou-
bling of the vascular density.
Knockdown of CLDN3 and CLDN4 Impairs TJ Formation
and Cell Adhesion
The ability of the parental, CLDN3KD, and CLDN4KD ovarian
cells to form TJ was examined by measuring transepithelial resistance.
Knockdown of CLDN3 and CLDN4 produced only a marginal de-
crease in transepithelial resistance (Figure 2A), but this was associated
with a significantly increased FITC-dextran flux (Figure 2B), reflecting
a disruption of the integrity of the TJ complex. Thus, impairment of
TJ formation was readily detectable in the CLDN knockdown cells.
Failure of TJ formation in the 2008 knockdown cells led to inves-
tigation of the effect of CLDN3 and CLDN4 knockdown on attach-
ment, migration, and invasion, all of which are modulated by the
ability of cells to form adhesions with their substrates or their neigh-
bors. Figure 2C shows that there was a 2.5-fold reduction in the frac-
tion of CLDN3KD cells, and a 2.2-fold reduction in the fraction of
CLND4KD cells, that had become attached to tissue culture dishes
when measured at 6 hours.
Knockdown of CLDN3 and CLDN4 Increases Cell
Migration and Invasion In Vitro
The effect on cell migration was compared using a Boyden two-
chamber assay in which the cells were induced to migrate through
a filter by the presence of FBS on the opposite side. As shown in
Figure 3A, migration was enhanced 1.4-fold by the knockdown of
CLDN3 and 1.9-fold by the knockdown of CLDN4. This motogenic
phenotype was confirmed in a wound-healing/scratch assay, a widely
accepted method for qualitative assessment of cell migration. The ex-
tent of wound closure can be taken as a direct measure of cell motility.
As shown in Figure 3B, the CLDN3KD cells closed the wound more
rapidly than the parental 2008 cells and the effect was even greater for
the CLDN4KD cells. The effect on invasive potential was examined
using a modified Boyden chamber invasion assay. The number of cells
that invaded through a layer of Matrigel was analyzed at 24 hours
after plating the cells on Matrigel-coated transwell inserts. As shown
in Figure 3C , knockdown of CLDN3 or CLDN4 expression in 2008
cells significantly increased their invasive potential by a factor of 2.9-fold
and 3.8-fold, respectively.
Conversely, we examined the effects of rescuing CLDN3 or CLDN4
expression by reintroduction of an siRNA-resistant CLDN3 or CLDN4
construct into the knockdown cells. In contrast to the knockdown
cells, re-expression of CLDN3 or CLDN4 slowed down cell migration
in wound-healing assay (Figure W2A) and decreased cell invasion
through the Matrigel (Figure W2B).
CLDN3 and CLDN4 Control Invasive and Metastatic Ability
The effect of CLDN3 and CLDN4 knockdown in metastatic
potential in vivo was examined by molecularly engineering the 2008,
CLDN3KD, and CLDN4KD cells to express the Ds-Red fluorescent
protein and then injecting 2 × 106 cells into the tail vein of nu/nu
mice. This allowed the appearance of metastases to be serially moni-
tored in living mice and their detection in organs freshly removed from
the mouse by fluorescent imaging. Figure 4A shows fluorographs of
animals obtained with an IVIS 200 imaging system on day 42 post-
injection. Mice injected with either CLDN3KD or CLDN4KD cells
had significantly more lung metastases compared to mice injected with
2008 cells. On necropsy, lungs of injected mice were removed and ex-
amined with an Olympus OV100 fluorescence microscope. As shown
in Figure 4B, which presents representative images of fluorescent tumor
cell in mouse lung 6 weeks after tail vein injection, knockdown of
CLDN3 or CLDN4 remarkably increased the formation of metastases
to the lung and other sites compared with 2008 cells. Quantification
of total lung metastatic burden in the same sets of mice was per-
formed by measurement of Ds-Red fluorescence in lung homogenates.
Figure 2. Effect of CLDN3 and CLDN4 expression on TJ formation and cell adhesion. (A) TER in the monolayers of 2008, CLDN3KD, and
CLDN4KD cells 3 days after seeding onto the transwell inserts (n = 6). (B) Paracellular permeability of 4-kDa FITC-dextran measured on
day 3 after seeding the cells onto the transwell inserts. Vertical bars, ±SEM, n = 6. *P = 0.008 and **P = 0.001 (vs 2008 control).
(C) Relative adhesion quantified at 6 hours after seeding on uncoated tissue culture dishes. Vertical bars, ±SEM, n = 4. *P = 0.001 and
**P = 0.003 (vs 2008 control).
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Figure 4C shows that there was a 1.7-fold and a 2.4-fold increase
of red fluorescence, respectively, in the lungs of CLDN3KD- and
CLDN4KD-injected mice. Hematoxylin and eosin staining of fixed
and paraffin-embedded tissue confirmed the presence of micrometas-
tases in the lungs (Figure 4D). Thus, the anti-invasive effect of CLDN3
and CLDN4 detected in the Matrigel invasion assay was confirmed
in vivo, and the results document a large enhancement of metastatic
potential when either CLDN3 or CLDN3 is reduced.
To determine whether increasing the expression of either CLDN3
or CLDN4 in a cell line that does not express either claudin would pro-
duce an opposite effect, we used the HEY human ovarian cell line in
which CLDN3 and CLDN4 are undetectable. HEY cells were infected
with lentiviral vectors expressing either CLDN3 or CLDN4, and con-
stitutively expressing populations were tested for changes in cell migra-
tion using the wound-healing assay and for invasion in the Boyden
chamber assay. Consistent with what was observed with 2008 and its
CLDN3 or CLDN4 knockdown sublines, forced expression of either
CLDN3 or CLDN4 in the HEY cells reduced cell migration and in-
vasion (Figure 5, A and B). When inoculated subcutaneously (SC),
HEY-CLDN3 and HEY-CLDN4 tumors grew 1.4-fold (P = 0.007)
and 1.8-fold (P = 0.005) more slowly than the parental HEY tumors
(Figure 5C). Expression of CLDN3 or CLDN4 inHEY cells significantly
reduced their invasive potential as evidenced by the reduced ability to
colonize the lungs of the immunocompromised mice (Figure 5D).
The loss of transepithelial resistance that accompanied knockdown
of CLDN3 or CLDN4 raised the question of their effect on the other
major proteins found in TJ including occludin, JAM, and ZO-1. As
shown in Figure W3A, Western blot analysis disclosed that there was
a marginal decrease in the levels of occludin and ZO-1 but a moder-
ate increase in the expression levels of JAM in the CLDN3KD or
CLDN4KD cells. The effect on occludin was examined in more detail
by immunocytochemical staining and laser scanning confocal micro-
scopic analysis. This revealed that the intensity of staining for occludin
was somewhat reduced in the CLDN3KD or CLDN4KD cells but
that the relative membrane versus cytoplasmic intensity and subcellular
location was not altered (Figure W3, B and C). These results indicate
that knockdown of either CLDN3 or CLDN4 did not produce major
changes in the level of these other TJ proteins.
CLDN3 and CLDN4 Regulate E-cadherin Expression and
Affect β-catenin Signaling
Suppression of E-cadherin expression is regarded as one of the main
molecular events responsible for dysfunction in cell-cell adhesion. Most
tumors have abnormal cellular architecture, and the loss of E-cadherin
is a well-known prerequisite for tumor cell invasion. However, a direct
protein-protein or genetic interaction between CLDN3 or CLDN4
and E-cadherin has not been reported in any organism and little is
known about the regulation of E-cadherin expression by claudins in
ovarian carcinomas. Interestingly, knockdown of CLDN3 expression
in the ovarian carcinoma 2008 cells was accompanied by a 55% de-
crease in E-cadherin expression at the protein level and almost complete
loss of expression in the CLDN4KD cells (Figure 6A). Measurement
of E-cadherin mRNA levels by quantitative RT-PCR showed a 60 ±
11.8% reduction in the CLDN3KD cells and an 83 ± 3.5% decrease
in the CLDN4KD cells (Figure 6B), indicating that E-cadherin is
downregulated at the transcriptional level similar to the claudins them-
selves. It is noteworthy that the transcription factor Snail has been
reported to bind to E-boxes in the promoters of both E-cadherin and
claudins and suppress their expression [50,52,53].
Figure 3. CLDN3 and CLDN4 control tumor cell migration and in-
vasion. (A) Relative migration through an uncoated filter toward
serum-containing medium in a Boyden chamber assay. The migra-
tory ability of cells was compared by measuring the number of cells
migrating through the uncoated filters. Vertical bars, ±SEM, n = 6.
*P= 0.035 and **P= 0.005 (vs 2008 control). (B) Relative motility as
determined by the ability of 2008, CLDN3KD, and CLDN4KD cells
to close a wound made by creating a scratch through a lawn of con-
fluent cells. (C) Relative invasion of cells through a layer of Matrigel
coated on the filter of a Boyden chamber measured at 24 hours after
seeding. Vertical bars, ±SEM, n = 6. *P = 0.004 and **P = 0.002
(vs 2008 control).
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Since the intracellular domains of E-cadherin directly bind to and
sequester cytoplasmic β-catenin, E-cadherin serves as a negative reg-
ulator that functionally blocks the β-catenin signaling pathway that
guides cell fate decisions through the regulation of cell growth, motility,
and survival [54]. This led us to investigate whether the cytoplasmic
and/or nuclear accumulation of β-catenin was regulated by CLDN3
and CLDN4. In the CLDN3KD cells, there was a 1.1-fold and a
1.5-fold increase of β-catenin in the cytoplasm and nuclei, respectively,
whereas increases of 2.5-fold and 2.0-fold were found in the CLDN4
knockdown cells (Figure 7A). Furthermore, immunocytochemical
analysis with the same antibody confirmed increased levels of nuclear
β-catenin in the knockdown sublines with the effect being greater in
the CLDN4KD than the CLDN3KD cells (Figure 7B). Cytosolic
β-catenin is targeted for degradation when phosphorylated by GSK-3β,
the kinase primarily responsible for phosphorylating β-catenin. As phos-
phorylation of GSK-3β itself on Ser9 inhibits its activity and prevents
targeting of β-catenin for degradation, we next determined whether
the observed increase of β-catenin was correlated with the phosphoryla-
tion state of GSK-3β. Indeed, a significant increase in the level of
Ser9-phosphorylated and therefore inactive GSK-3β was found in the
CLDN3KD and CLDN4KD cells compared with the 2008 control
(Figure 7C ). In line with this, a significant increase in the active (de-
phosphorylated) pool of nuclear β-catenin was observed in CLDN3KD
and CLDN4KD cells (Figure 7D). To further confirm the increase in
nuclear β-catenin, we transfected cells with the TOPflash luciferase re-
porter construct to evaluate changes in β-catenin–regulated promoter
activation. Transfection with this TCF- and β-catenin–dependent re-
porter plasmid demonstrated a 1.7-fold increase of reporter gene activ-
ity in the CLDN3KD cells and a 2.6-fold increase in the CLDN4KD
cells (Figure 7E). An increase in the expression of the β-catenin/TCF-
regulated target gene cyclin D1 was also seen in the CLDN3KD and
CLDN4KD cells grown in vitro (Figure 7F ) and in vivo (Figure W4).
These results indicate that CLDN3 and CLDN4 regulate signaling
through the E-cadherin/β-catenin pathway.
Expression of CLDN3 and CLDN4 in the Fallopian Tubes
of Ovarian Cancer Patients
Many ovarian cancers express CLDN3 and CLDN4, but normal
ovarian surface epithelium does not; this seems to suggest that low ex-
pression of these claudins is associated with the benign state and high
Figure 4. CLDN3 and CLDN4 control metastatic potential of ovarian cells injected IV in nu/nu mice. (A) Fluorographs of mice 42 days
after tail vein injection of 2 × 106 2008, CLDN3KD, or CLDN4KD cells molecularly engineered to express Ds-Red showing more exten-
sive metastases when CLDN3 and CLDN4 are knocked down. (B) Representative fluorescent images of mouse lung lobes showing that
knockdown of CLDN3 and CLDN4 increases the extent of metastasis to lung when imaged at 42 days after tail vein injection. Scale bar,
2 mm. (C) Quantification of total lung metastasis burden in the five mice of each group. The lungs were dissected, homogenized, and
diluted for quantification of metastasis by red fluorescence. Vertical bars, ±SEM, n = 10. *P = 0.012 and **P = 0.001 (vs 2008 control).
(D) Hematoxylin and eosin staining of fixed and paraffin-embedded tissue confirmed the presence of micrometastases in the lungs of
mice injected with the CLDN4KD cells. Scale bar, 100 μm.
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expression with transformation. In light of the body of evidence indi-
cating that most ovarian cancers arise in the distal Fallopian tube [17–
20], we used histochemical analysis to examine the expression of
CLDN3 and CLDN4 in both the tumor and distal Fallopian tube from
the same patient in six cases of serous ovarian cancer. In all six cases,
both CLDN3 and CLDN4 were abundantly expressed in both sites
(Figure W5). This result is supportive of the concept that ovarian cancer
arises in an epithelium that normally expresses both of these claudins.
Our data suggest that those tumors that subsequently lose CLDN3
and CLDN4 expression can be expected to behave more aggressively.
Discussion
CLDN3 and CLDN4 are well known for their ability to affect TJ for-
mation and control paracellular permeability in epithelial monolayers.
The results reported here indicate that, in a fully malignant gynecologic
cancer cell line, these two claudins individually have quite large effects
Figure 5. Effect of claudin expression on cell migration and invasion in vitro as well as growth and metastasis in vivo. (A) Relative motility
as determined by the ability of HEY, HEY-CLDN3, and HEY-CLDN4 cells to close a wound made by creating a scratch through a lawn of
confluent cells. (B) Relative invasion of HEY, HEY-CLDN3, and HEY-CLDN4 cells through a Matrigel-coated layer on the filter of a Boyden
chamber measured at 12 hours after seeding. Vertical bars, ±SEM, n = 6. *P = 0.031 and **P = 0.014 (vs HEY control). (C) Relative
growth rate of HEY (▪), HEY-CLDN3 (▴), and CLDN4 (♦) tumors after SC inoculation of 1 × 106 cells in nu/nu mice (n= 16 for each tumortype). (D) Quantification of total lung metastatic burden as determined by measurement of extractable mCherry fluorescence at 43 days
after tail vein injection of mCherry-labeled HEY, HEY-CLDN3, and HEY-CLDN4 cells. Vertical bars, ±SEM, n = 10. *P = 0.009 and **P =
0.005 (vs HEY-mCherry control).
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on tumor growth rate and metastatic potential. The increased in vivo
growth rate can be largely explained by an increased birth rate and de-
creased death rate of tumor cells and by an increase in vascular density,
but the fact that knockdown of these claudins does not change the
in vitro growth rate or significantly perturb cell cycle phase distribution
indicates that these are the result of alterations in the interaction of the
tumor cell with its in vivo environment rather than cell autonomous
effects. Knockdown of CLDN3 or CLDN4 was accompanied by
enhanced migration, increased invasion, and greater in vivo metastatic
colonization of the lungs. That these effects were specific to the reduc-
tion in CLDN3 and CLDN4 was shown by the fact that re-expression
of an siRNAi-resistant CLDN3 or CLDN4 mRNA in the knockdown
cells, or forced expression of CLDN3 or CLDN4 in the HEY cells
that do not express endogenous CLDN3 or CLDN4, slowed tumor
growth and reduced lung metastases. It is noteworthy that the effect
of knocking down CLDN4 was consistently greater than that of knock-
ing down CLDN3 in the panel of assays reported here.
Most cells express multiple claudin isoforms that interact in a homo-
typic and heterotypic manner to regulate junctional permeability and
confer selectivity and strength to the TJ. At least five pairs of claudin
genes (CLDN3 and CLDN4, CLDN6 and CLDN9, CLDN8 and
CLDN17, CLDN10 and CLDN15, and CLDN22 and CLDN24) have
been found to be closely linked with respect to their close proximity in
the human genome [55]. Whether this genomic arrangement leads to
coordinate regulation is currently unknown, but, at least in the case
of CLDN3 and CLDN4, coordinate expression has been reported in
several normal and neoplastic tissues [27], and expression of these genes
is frequently simultaneously elevated in a variety of cancers [39]. The
similarity of the phenotype produced by knockdown of either CLDN3
or CLDN4 raised the question of whether these proteins function as
a single unit whose effectiveness or stability is impaired when either
is missing. The knockdown of CLDN3 was found to produce a signif-
icant reduction in the level of CLDN4 as determined by Western blot
analysis (Figure W1B). Similarly, knockdown of CLDN4 substantially
reduced the CLDN3 protein level. However, quantitative RT-PCR
analysis of mRNA levels indicated that this was not just due to reduced
stability of one protein in the absence of its putative partner since re-
duction in CLDN3 mRNA was accompanied by reduction in CLDN4
mRNA and vice versa (Figure W1A). Rather than being an off-target
effect of the shRNAi, this is likely due to the fact that the promoters of
both genes are sensitive to the same transcriptional repressors that are
activated when either one or the other mRNA is reduced [23,50,51].
Knockdown of CLDN3 and CLDN4 was accompanied by re-
duced expression of E-cadherin at both the mRNA and protein levels.
Knockdown of CLDN3 reduced E-cadherin mRNA by 60% and pro-
tein by 55%; the effect on CLDN4KD was greater with an 83% de-
crease in mRNA and a >95% reduction in protein. This suggests that a
major component of the effect of CLDN3 and CLDN4 on E-cadherin
expression is at the transcriptional level. Knockdown of CLDN3 and
CLDN4 did not alter the expression of the proteins with which it is
most intimately associated in TJs, suggesting that the reduction in
E-cadherin was not part of a general failure of trafficking of proteins
to sites of cell-cell contact. The mechanism by which loss of CLDN3
and CLDN4 trigger E-cadherin down-regulation remains to be de-
fined, but it is noteworthy that loss of E-cadherin expression is a char-
acteristic feature of cells that have gone through an EMT, and some
of the transcription factors that control this process can act as transcrip-
tional repressors of the E-cadherin promoter [52,56].
Loss of E-cadherin expression in polarized epithelial cells activates
the β-catenin signaling pathway [54], and the down-regulation of
E-cadherin that accompanied loss of CLDN3 or CLDN4 in the non-
polarized malignant ovarian cancer cells produced the same effect.
Knockdown of either CLDN3 or CLDN4 produced an increase in
Ser9 phosphorylation of GSK-3β known to reduce the ability of
GSK-3β to mediate the degradation of β-catenin. This was accom-
panied by an increase in total nuclear β-catenin as documented both
by Western blot and immunocytochemical analyses, an increase in
the active dephosphorylated form of β-catenin, enhanced β-catenin
transcriptional activity as detected by the TOPflash reporter, and an
increase in cyclin D1. In other cell systems, loss of E-cadherin is asso-
ciated with increased signaling in other pathways as well [57]. Whether
the increase in β-catenin by itself accounts for the enhanced 2008
growth rate and metastatic seeding or whether additional pathways
are also involved remains to be determined. However, the results of
this study indicate that both CLDN3 and CLDN4 function upstream
of E-cadherin to limit growth rate, migration, invasion, and metastasis.
The majority of ovarian cancers express CLDN3 and CLDN4 at
high levels [12,13,58]. The results reported here lead to the prediction
that those ovarian cancers that do not express these claudins should
behave more aggressively. As there is an increasing body of evidence
suggesting that serous ovarian cancers arise from the distal Fallopian
tubes rather than the ovarian surface epithelium, we have performed
an immunohistochemical analysis of the expression of CLDN3 and
CLDN4 in the Fallopian tubes of six patients with serous ovarian can-
cer. Consistent with the fact that most serous ovarian cancers express
high levels of CLDN3 and CLDN4, we found that the distal Fallopian
Figure 6. CLDN3 and CLDN4 regulate the expression of E-cadherin.
(A)Westernblot analysis showing reducedexpression of E-cadherin in
CLDN3KD and CLDN4KD cells. (B) The relative levels of E-cadherin
mRNA measured by real-time RT-PCR in CLDN3KD and CLDN4KD
cells compared with 2008 cells. Vertical bars, ±SEM, n = 5. *P =
0.006 and **P = 0.002 (vs 2008 control).
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Figure 7. Activation of β-catenin signaling on knockdown of CLDN3 and CLDN4. (A) Western blot analysis showing increased nuclear
dephospho (active)–β-catenin levels in CLDN3KD and CLDN4KD cells. Relative levels of cytoplasmic and nuclear β-catenin were nor-
malized against α-tubulin and histone H1, respectively, and expressed relative to the control from the mean of three separate analyses.
(B) Immunocytochemical analysis of 2008, CLDN3KD, and CLDN4KD cells stained with antibody to β-catenin showing increased nuclear
localization of β-catenin in the knockdown cells. (C) Western blot analysis showing increased GSK-3β phosphorylation in CLDN3KD and
CLDN4KD cells. Relative levels of phospho–GSK-3β were normalized against total GSK-3β. The ratio in control 2008 cells is designated
as 1. (D) Western blot analysis showing increased nuclear dephospho–β-catenin levels in CLDN3KD and CLDN4KD cells. Relative levels
of active β-catenin (dephosphorylated form) were normalized against total β-catenin. The ratio in control 2008 cells is designated as 1.
(E) Activation of β-catenin/TCF signaling in CLDN3KD and CLDN4KD cells. Cells were transiently co-transfected with the firefly luciferase
TOPflash TCF reporter plasmid and the control plasmid pCMXβgal to normalize for transfection efficiency. The luciferase values were
normalized for variations in transfection efficiency and are expressed as fold stimulation of luciferase activity compared with the 2008
control cultures. Vertical bars, ±SEM, n = 5. *P = 0.086 and **P = 0.016 (vs 2008 control). (F) Cyclin D1 protein levels in CLDN3KD and
CLDN4KD cells relative to that in the 2008 cells were calculated densitometrically after normalization to the level of α-tubulin.
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tubes of patients with serous ovarian cancer express these proteins in
abundance. This new information provides a more logical explanation
of the relationship betweenCLDN3 andCLDN4 expression and tumor
behavior that parallels what is known about “high” versus “low” claudin
breast cancers. As for ovarian carcinomas, serous ovarian cancer ap-
pears to arise in an epithelium that normally expresses CLDN3 and
CLDN4 as such the distal Fallopian tube. While limited and contra-
dictory evidence is available from studies of ovarian cancer [59,60], dis-
ruption of cell-cell adhesions correlates with progression, invasion, and
metastasis in breast cancer [9,41,42], and low expression of CLDN4 is
associated with poor prognosis in some subtypes of breast [22,43,44],
pancreatic [26], and colon cancers [24,25]. Our data support the con-
cept that those cancers that continue to express these proteins are less
aggressive than those in which their expression is lost.
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Figure W1. Knockdown of CLDN3 or CLDN4 does not alter in vitro growth and has only small effects on cell cycle phase distribution.
(A) Relative CLDN3 and CLDN4 mRNA levels in the parental 2008, 2008-scb, CLDN3KD, and CLDN4KD cells. Vertical bars, ±SEM, n = 5.
*P= 0.001 and **P= 0.016 (vs 2008 control); #P= 0.008 and ##P= 0.006 (vs 2008 control). (B) Relative expression of CLDN3 and CLDN4
as determined byWestern blot analysis normalized to the level of β-actin. (C) Cell proliferation as a function of time; 2008 (▪), CLDN3KD (⋄),and CLDN4KD (◯) cells were cultured for the indicated periods and relative cell growth was determined by cell counting kit-8 (CCK-8) assay
(n = 4). (D) FACS analysis of cell cycle phase distribution of subconfluent cell populations showing small increase in G0/G1 and decrease in
S phase fraction in CLDN3KD and CLDN4KD cells (n = 3).
Figure W2. Effect of rescuing expression of CLDN3 or CLDN4 in the knockdown cells on cell migration and invasion. (A) Relative motility as
determined by the ability of CLDN3KD, CLDN4KD, CLDN3KD-3 rescue, and CLDN4KD-3 rescue cells to close a wound made by creating
a scratch through a lawn of confluent cells. (B) Relative invasion of 2008, CLDN3KD, CLDN4KD, CLDN3KD-3 rescue, and CLDN4KD-4
rescue cells through a Matrigel-coated layer on the filter of a Boyden chamber measured at 12 hours after seeding. Vertical bars, ±SEM,
n = 3. *P = 0.032 (vs CLDN3KD) and **P = 0.001 (vs CLDN4KD).
Figure W3. Knockdown of CLDN3 or CLDN4 does not affect the level of expression of other TJ proteins. (A) Western blot analysis of
occludin, JAM-1 and ZO-1 expression in 2008, CLDN3KD, and CLDN4KD cells. Relative levels shown numerically are the mean of three
separate analyses normalized to β-actin. (B) Immunocytochemical analysis of 2008, CLDN3KD, and CLDN4KD cells stained with antibody
to occludin showing equivalent expression in all three cell lines. Scale bar, 10 μm. (C) The upper row shows a superimposed stacked series
of Z-scan confocal images from the top to the bottom of the cell. The lower row shows a single confocal section through the middle of
each cell. Scale bar, 1 μm.
Figure W4. Immunohistochemical staining of 2008, CLDN3KD, and CLDN4KD tumors for expression of cyclin D1 (brown). Scale bar, 20 μm.
Figure W5. Immunohistochemical staining for CLDN3 and CLDN4 of serial sections of serous ovarian carcinoma and distal Fallopian
tube from the same patient. Insets for the colonic mucosa control show staining in the absence of the primary antibody. For images of
tumor and Fallopian tube, magnification is 10× and insets are 40×.
